- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biocon Biologics Pairs Digital Therapeutics With Insulin
In a deal with Voluntis, Biocon Biologics aims to extend the appeal of its insulin products by offering a digital titration device for self-management of insulin dosage.
Biocon Biologics, specializing in biosimilars and insulin, said it has teamed up with Voluntis, a digital products health care company, to market an FDA-approved product that provides automated insulin dose recommendations to help individuals with diabetes self-manage their condition.
The product, Insulia, also enables health care teams to monitor by remote. It will be marketed to patients with type 2 diabetes using Biocon Biologics—brand insulins, which include recombinant human insulin, insulin glargine, and insulin aspart.
Under terms of the agreement, Biocon will distribute the product in several markets worldwide.
The company said Insulia is the first digital therapeutic with regulatory approval for providing automated titration recommendations for basal insulins. Insulia also has CE (Conformité Européenne) marking, meaning that it conforms to European Economic Area manufacturing standards.
“The demand for at-home treatment and telemedicine solutions is dramatically increasing around the world,” Biocon said in a statement.
“We believe pairing our products with a digital therapeutic solution will help improve patient outcomes and reduce costs to health care systems in the long term. We remain committed to impact patients’ lives through innovative solutions,” said Christiane Hamacher, CEO and managing director of Biocon.
Earlier this year, Biocon's parent company, Biocon Limited, announced plans to take the biosimilars unit public in an initial public offering of yet-undetermined valuation.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
February 10th 2024The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.
Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings
January 23rd 2024Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.
